Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Trading involves risk
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
English (International)
Regeneron Pharmaceuticals Inc
Closed
SectorHealthcare
547.43 2.38
Overview
Share price change
24h
Min
530.98
Max
551.25
Income | -109M 809M |
|---|---|
Sales | -761M 3B |
P/E Sector Avg | 13.352 40.527 |
EPS | 8.22 |
Dividend yield | 0.67 |
Profit margin | 26.701 |
Employees | 15,158 |
EBITDA | -54M 1B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +36.86% upside |
Dividend yield Sector Avg | 0.67% 2.40% |
|---|---|
Next Earnings | 1 Aug 2025 |
Market Cap | -18B 57B |
|---|---|
Previous open | 545.05 |
Previous close | 547.43 |
News Sentiment
By Acuity
34%
66%
86 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Regeneron Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Regeneron Pharmaceuticals Inc Forecast
Price Target
By TipRanks
36.86% upside
12 Months Forecast
Average 732.1 USD 36.86%
High 900 USD
Low 535 USD
Based on 24 Wall Street analysts offering 12 month price targets forRegeneron Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
86 / 380 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
